News

Carlyle Credit Income Fund Latest Quarterly Performance Insights

Carlyle Credit Income Fund Latest Quarterly Performance Insights

Recent Financial Performance of Carlyle Credit Income Fund

Carlyle Credit Income Fund (NYSE: CCIF) recently shared its financial results for the third quarter, showcasing significant developments that reflect its ability to navigate a complex market. With a commitment to providing value to its shareholders, the Fund’s performance remains strong amidst market fluctuations.

Strong Portfolio Management

Nishil Mehta, the Principal Executive Officer and President of CCIF, expressed confidence in the Fund's quarterly performance, emphasizing its resilience. The Fund continues to manage a diversified portfolio of collateralized loan obligations (CLOs), allowing it to leverage the expertise of third-party managers effectively. This diversification plays a crucial role in maintaining stability and flexibility during uncertain financial periods.

Key Achievements Over the Quarter

In the past quarter, CCIF achieved notable milestones:

  • The Fund has upheld a steady monthly dividend of 10.5 cents, projected to last through November 2025. This equates to an impressive annualized dividend yield of 22.07% based on share prices.
  • CCIF successfully funded $28.1 million in new CLO investments, highlighting a strong weighted average GAAP yield of 14.56%. Overall, the portfolio's weighted average GAAP yield stood at 15.11% as of the latest reporting period.
  • In line with its capital management strategies, the Fund sold 1.4 million common shares via its At-The-Market (ATM) offering, securing net proceeds of $9.2 million.
  • The Fund converted $5.0 million of its Series B Convertible Preferred Shares into common shares, further enhancing shareholder value.

Investment Income Metrics

During this quarter, CCIF reported net investment income of $0.19 per common share. The adjusted net investment income reached $0.22 per common share, while the core net investment income stood at $0.35 per common share. Notably, the net asset value per common share as of the reporting date was $6.51, with a total fair value of investments reaching $200.4 million.

Dividends Declared

In alignment with its commitment to returning capital to investors, CCIF declared its monthly dividend for the common stock at $0.1050 for September, October, and November 2025. Furthermore, shareholders of the 8.75% Series A Term Preferred Shares will receive dividends of $0.1823 per share during the same period.

Upcoming Conference Call

CCIF will host a conference call to discuss these results in greater detail on a date soon to be announced. This call will serve as a platform for investors to gain insights into the Fund's strategies and future direction.

About Carlyle Credit Income Fund

Carlyle Credit Income Fund focuses on equity and junior debt tranches of CLOs, drawing on a diverse portfolio primarily comprised of U.S. senior secured loans. Managed by Carlyle Global Credit Investment Management L.L.C., the Fund benefits from the vast resources and capabilities of one of the largest CLO managers globally.

Frequently Asked Questions

1. What are the financial highlights for CCIF in this quarter?

CCIF reported net investment income of $0.19 per common share and maintained a stable monthly dividend of 10.5 cents.

2. How does CCIF's dividend yield compare to previous periods?

The current annualized dividend yield is 22.07% based on the share price, reflecting a strong commitment to returning value to shareholders.

3. What investments did CCIF undertake this quarter?

The Fund funded $28.1 million in new CLO investments, showcasing an average GAAP yield of 14.56%.

4. Who manages the Carlyle Credit Income Fund?

The Fund is externally managed by Carlyle Global Credit Investment Management L.L.C., a subsidiary of Carlyle.

5. Where can I find more information about CCIF?

More detailed information can be accessed on the Carlyle Credit Income Fund website, which includes performance reports and investor resources.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Novartis Pulls the Plug on BioArctic Agreement

Updated Category News Views 57

Novartis Drops BioArctic Like a Hot Potato Well, folks, it looks like Novartis has decided to pack up its bags and hightail it out of its collaboration with BioArctic AB. This ain't just any small piece of news—it's got ramifications that have folks in the biotech and healthcare sector scratching their heads and, probably, feeling a mixture of apprehension and...

Continue Reading
NABEP Powers Ahead with Orinoco Furnace Restart

Updated Category News Views 142

Revving Up the Engines in the Orinoco Belt And HERE we are again, ringing the bell on another bold move in the world of energy. NABEP is pulling back the curtain on their revamped activities in the Orinoco Belt. You're telling me they just fired up one heck of a furnace? In this relentless pursuit to spike their output, you've gotta respect the hustle. It's like cranking...

Continue Reading
Differentia Bio's AI: Transforming Drug Development Dynamics

Updated Category News Views 51

The Future of Drug Development: AI's New Role When it comes to pharmaceutical R&D, Some outfits are playing pin the tail on the donkey, but Differentia Bio over here is sharpening the pin with some futuristic gadgetry. Yep, they're jazzing up the game with AI-powered digital twins, building lifelike disease environments that predict therapeutic outcomes with precision...

Continue Reading
Business Formations in 2026: A Blow-by-Blow Analysis

Updated Category News Views 47

Surging Entrepreneurial Spirit in 2026 Just when you’d think economic jitters would slow us down, American entrepreneurship is out there smashing records like a bulldozer through a picket fence. September 2026 saw a staggering 562,579 new business formations—the highest September tally ever logged. That's no fluke. This momentum hasn’t let up all year, and it paints...

Continue Reading
TEKLYNX 2026: Revolutionizing Barcode Labeling Tech

Updated Category News Views 40

In the ever-evolving world of supply chain technology, a big move by TEKLYNX is making waves. The 2026 version of their barcode labeling software isn't just an upgrade—it's a full-blown transformation. They've fine-tuned their suite to align with the latest industry standards and integrated fresh capabilities that scream future-proofing. TEKLYNX's Game-Changing Upgrades...

Continue Reading
Hunan Courts European Investors with Strategic Initiatives

Updated Category News Views 74

Seizing the European Spotlight You've heard of places making a splash, but Hunan smashing through the scene in Europe? Now that's a move you don't see every day. This Chinese province is dead set on stealing the European investment show, with a slick meet-and-greet tour across Germany and Switzerland. What's cooking in Hunan isn't your typical rice porridge—it's a...

Continue Reading
Waters Acquires MOBILion: Ion Mobility Meets AI

Updated Category News Views 18

MOBILion Joins Waters' Fold: A New Era for Proteomics Ah, the biotech world just saw another big whirl with Waters Corporation snagging MOBILion Systems. Now, this isn't just some stroll in the market park. We're talking about weaving MOBILion's fancy high-resolution ion mobility separation tech right into Waters' already robust mass spectrometry setup. These folks are...

Continue Reading
KOVE's Bold Lineup Expansion at EICMA 2026

Updated Category News Views 0

What's Roaring: The Latest from KOVE Anybody who’s been following motorcycle trends knows that EICMA 2026 was destined to be a spectacle, and KOVE didn’t disappoint. They rolled out a fleet of five new models, including the 125 RALLY, 350 RALLY, 650RR, and two head-turners on the electric front: the BONIC and the E-500RR. Each model brings something fresh to the...

Continue Reading
Qapture's Institutional Stablecoin Venture Unveiled

Updated Category News Views 26

Stablecoin Strategy Meets Institutional Investment Here's a fresh one from the digital asset universe. We're talking about Qapture Investments' bold move to launch an institutional-grade stablecoin yield strategy. This ain't your average kitchen table crypto chat—it's the Qapture Safe Haven Vault (QHVN-USD), tailored for those looking to get a better return on their...

Continue Reading
How Octopus AI Reinvents Financial Processes in 2026

Updated Category News Views 56

Stepping into 2026, the buzz in enterprise finance isn’t about a new gadget or slick marketing trick; it's about complex financial processes being tamed by artificial intelligence. Octopus AI is trying to spearhead this transition by automating the intricacies of financial workflows while ensuring that human judgment remains at the helm. The Austin, Texas outfit laid...

Continue Reading

Top 5 Most Recently Viewed Articles

Skyline Medical Faces High Market Pressure with POAI Low at $0.64

Updated Category News Views 93

Skyline Medical Inc. Stock Reaches New Low In the face of a volatile market, Skyline Medical Inc. (POAI) has seen its stock price fall to a concerning 52-week low of $0.64. This sharp decline represents an 81.66% drop over the past year, revealing the significant challenges the company has encountered. Investors are keeping a close watch on POAI's efforts to stabilize...

Continue Reading
Foresight Diagnostics Validates CLARITY MRD Assay for DLBCL

Updated Category News Views 308

Foresight Diagnostics Validates CLARITY MRD Assay for DLBCL Treatment Foresight Diagnostics, a notable player in the diagnostics industry, has shared compelling new findings regarding its CLARITY Minimal Residual Disease (MRD) assay. This groundbreaking information was revealed during a multicenter study focused on frontline Diffuse Large B-Cell Lymphoma (DLBCL). The...

Continue Reading
Surge in Medical Tricorder Demand Drives Market Toward Growth

Updated Category News Views 123

Growing Demand for Medical Tricorders and Future Prospects The medical tricorder market is experiencing significant momentum, with a remarkable valuation of USD 3.7 billion in 2023. This industry is poised for substantial growth, projected to reach USD 6.3 billion by 2032. The compound annual growth rate (CAGR) expected from 2024 to 2032 is approximately 6.1%. The driving...

Continue Reading
Catalis Dental Lab Partners Broadens Reach with New Facility

Updated Category News Views 152

Catalis Dental Lab Partners Expands with New Acquisitions Catalis Dental Lab Partners has reached two significant milestones in its expansion efforts. The company announced the acquisition of Revolution Dental Lab and the launch of a cutting-edge Digital Design Center focused on servicing dental professionals more effectively. Acquisition of Revolution Dental Lab As part...

Continue Reading
Pacific West Bancorp Reports Noteworthy Q2 Financial Achievements

Updated Category News Views 151

Pacific West Bancorp Posts Strong Second Quarter Results Pacific West Bancorp (PWBK), the holding company of Pacific West Bank, recently disclosed its second quarter financial results, revealing a net income of $130 thousand or $0.05 per diluted share. This financial outcome underscores the company's commitment to its growth strategy, as they continue to strengthen their...

Continue Reading